The US Biotechnology Industry Organization has hailed President Barack Obama's call for a national target of 3% of the nation's Gross Domestic Product to be spent on scientific R&D. Jim Greenwood, the BIO's president and chief executive, said: "America's biotechnology community thanks Pres Obama for setting this ambitious goal. As the President said: 'science is more essential for our prosperity, our security, our health, our environment and our quality of life than it has ever been.' We couldn't agree more."
Mr Greenwood emphasized the 1.3 million people employed in the US bioscience sector, arguing that "our industry can help drive economic growth in innovation industries," including pharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze